ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
November 16, 2017 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update
November 09, 2017 16:05 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
August 16, 2017 08:30 ET
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
August 09, 2017 16:30 ET
|
ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
August 03, 2017 16:15 ET
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
June 20, 2017 08:30 ET
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA ...
ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio
March 19, 2014 07:05 ET
|
ARCA biopharma, Inc.
WESTMINSTER, CO--(Marketwired - Mar 19, 2014) - ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today...